<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Polycomb repressive complexes &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/polycomb-repressive-complexes/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Oct 2026 00:24:24 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Polycomb repressive complexes &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Childhood Brain Tumor Study Exposes KDM2B as a Treatable Weak Spot in High-Risk Medulloblastoma</title>
		<link>https://bioengineer.org/childhood-brain-tumor-study-exposes-kdm2b-as-a-treatable-weak-spot-in-high-risk-medulloblastoma/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 16 Oct 2026 00:24:24 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chromatin regulation]]></category>
		<category><![CDATA[epigenetics]]></category>
		<category><![CDATA[Group 3 medulloblastoma]]></category>
		<category><![CDATA[Group 4 medulloblastoma]]></category>
		<category><![CDATA[histone modifications]]></category>
		<category><![CDATA[KDM2B]]></category>
		<category><![CDATA[medulloblastoma]]></category>
		<category><![CDATA[pediatric brain tumor]]></category>
		<category><![CDATA[Polycomb repressive complexes]]></category>
		<category><![CDATA[PRC2]]></category>
		<category><![CDATA[preclinical models]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=421366</guid>

					<description><![CDATA[A comprehensive epigenetic analysis led by St. Jude and KiTZ identified the chromatin regulator KDM2B as an essential, selective dependency in Group 3 and Group 4 medulloblastoma, pointing to new targeted therapy options for these high-risk childhood brain tumors.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">421366</post-id>	</item>
	</channel>
</rss>
